279 related articles for article (PubMed ID: 36871057)
41. Epigenomics and epigenetic therapy of cancer.
Brown R; Strathdee G
Trends Mol Med; 2002; 8(4 Suppl):S43-8. PubMed ID: 11927287
[TBL] [Abstract][Full Text] [Related]
42. The role of epigenetics in T-cell lymphoma.
Yamagishi M
Int J Hematol; 2022 Dec; 116(6):828-836. PubMed ID: 36239901
[TBL] [Abstract][Full Text] [Related]
43. Genomic pathway analysis reveals that EZH2 and HDAC4 represent mutually exclusive epigenetic pathways across human cancers.
Cohen AL; Piccolo SR; Cheng L; Soldi R; Han B; Johnson WE; Bild AH
BMC Med Genomics; 2013 Sep; 6():35. PubMed ID: 24079712
[TBL] [Abstract][Full Text] [Related]
44. Recent Clinical Update of Acute Myeloid Leukemia: Focus on Epigenetic Therapies.
Lee E; Koh Y; Hong J; Eom HS; Yoon SS
J Korean Med Sci; 2021 Apr; 36(13):e85. PubMed ID: 33821592
[TBL] [Abstract][Full Text] [Related]
45. Identification of coexistence of DNA methylation and H3K27me3 specifically in cancer cells as a promising target for epigenetic therapy.
Takeshima H; Wakabayashi M; Hattori N; Yamashita S; Ushijima T
Carcinogenesis; 2015 Feb; 36(2):192-201. PubMed ID: 25477340
[TBL] [Abstract][Full Text] [Related]
46. Emerging Epigenetic Therapies for Brain Tumors.
Kukreja L; Li CJ; Ezhilan S; Iyer VR; Kuo JS
Neuromolecular Med; 2022 Mar; 24(1):41-49. PubMed ID: 34677796
[TBL] [Abstract][Full Text] [Related]
47. [The role of epigenetics in malignant lymphoma].
Yamagishi M
Rinsho Ketsueki; 2022; 63(9):1157-1166. PubMed ID: 36198541
[TBL] [Abstract][Full Text] [Related]
48. EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed/refractory follicular lymphoma.
Julia E; Salles G
Future Oncol; 2021 Jun; 17(17):2127-2140. PubMed ID: 33709777
[TBL] [Abstract][Full Text] [Related]
49. Advances in epigenetic therapeutics with focus on solid tumors.
Jin N; George TL; Otterson GA; Verschraegen C; Wen H; Carbone D; Herman J; Bertino EM; He K
Clin Epigenetics; 2021 Apr; 13(1):83. PubMed ID: 33879235
[TBL] [Abstract][Full Text] [Related]
50. Histone Deacetylases (HDACs) Guided Novel Therapies for T-cell lymphomas.
Zhang Q; Wang S; Chen J; Yu Z
Int J Med Sci; 2019; 16(3):424-442. PubMed ID: 30911277
[TBL] [Abstract][Full Text] [Related]
51. Epigenetic treatment combinations to effectively target cisplatin-resistant germ cell tumors: past, present, and future considerations.
Oing C; Skowron MA; Bokemeyer C; Nettersheim D
Andrology; 2019 Jul; 7(4):487-497. PubMed ID: 30924611
[TBL] [Abstract][Full Text] [Related]
52. The Advances in Epigenetics for Cancer Radiotherapy.
Wang Y; Han Y; Jin Y; He Q; Wang Z
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628460
[TBL] [Abstract][Full Text] [Related]
53. Indolent lymphomas: pushing the pace with novel agents.
Jacobson CA
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):279-286. PubMed ID: 31808854
[TBL] [Abstract][Full Text] [Related]
54. Diagnosis and treatment of lymphomas in the era of epigenetics.
Chebly A; Chouery E; Ropio J; Kourie HR; Beylot-Barry M; Merlio JP; Tomb R; Chevret E
Blood Rev; 2021 Jul; 48():100782. PubMed ID: 33229141
[TBL] [Abstract][Full Text] [Related]
55. HDACs and the epigenetic plasticity of cancer cells: Target the complexity.
Brancolini C; Gagliano T; Minisini M
Pharmacol Ther; 2022 Oct; 238():108190. PubMed ID: 35430294
[TBL] [Abstract][Full Text] [Related]
56. Epigenetic mechanisms of tumor resistance to immunotherapy.
Arenas-Ramirez N; Sahin D; Boyman O
Cell Mol Life Sci; 2018 Nov; 75(22):4163-4176. PubMed ID: 30140960
[TBL] [Abstract][Full Text] [Related]
57. Epigenetic abnormalities of classical Hodgkin lymphoma and its effect on immune escape.
Liu Y; Huang R; Liu L; Meng Y; Liu X
Cell Biochem Funct; 2020 Apr; 38(3):242-248. PubMed ID: 31709594
[TBL] [Abstract][Full Text] [Related]
58. Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma.
Kikuchi J; Koyama D; Wada T; Izumi T; Hofgaard PO; Bogen B; Furukawa Y
J Clin Invest; 2015 Oct; 125(12):4375-90. PubMed ID: 26517694
[TBL] [Abstract][Full Text] [Related]
59. Current clinical trials for epigenetic targets and therapeutic inhibitors for pancreatic cancer therapy.
Ganji C; Farran B
Drug Discov Today; 2022 May; 27(5):1404-1410. PubMed ID: 34952224
[TBL] [Abstract][Full Text] [Related]
60. [Epigenetic aberrations in adult T-cell leukemia/lymphoma and development of a novel EZH1/2 inhibitor].
Yamagishi M
Rinsho Ketsueki; 2018; 59(4):432-438. PubMed ID: 29743404
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
